Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Jun 28;10(4):811-5.
doi: 10.1177/1932296816638923. Print 2016 Jul.

Quality Control of Insulins and Biosimilar Insulins: What Do We Know?

Alan W Carter  1 , Lutz Heinemann  2 , David C Klonoff; Fellow AIMBE
Affiliations
Editorial

Quality Control of Insulins and Biosimilar Insulins: What Do We Know?

Alan W Carter et al. J Diabetes Sci Technol. .
No abstract available

Keywords: biosimilar insulin; insulin; quality; therapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: AWC has no conflicts to declare. LH is a member of a national and an international Advisory Board of Sanofi for Biosimilar Insulin. DCK is a consultant for Bayer, Insuline, Lifecare, and Voluntis and a stockholder in Tempramed.

References

    1. Owens DR, Landgraf W, Schmidt A, Bretzel RG, Kuhlmann MK. The emergence of biosimilar insulin preparations—a cause for concern? Diabetes Technol Ther. 2012;14(11):989-996. - PMC - PubMed
    1. Brinks V, Hawe A, Basmeleh AH, et al. Quality of original and biosimilar epoetin products. Pharm Res. 2011;28(2):386-393. - PMC - PubMed
    1. Generics and Biosimilars Initiative. Incomplete processing in recombinant streptokinase. May 29, 2015. Available at: http://www.gabionline.net/Biosimilars/Research/Incomplete-processing-in-.... Accessed February 16, 2016.
    1. Generics and Biosimilars Initiative. Protein aggregation and the generation of immune responses. March 14, 2014. Available at: http://www.gabionline.net/Biosimilars/Research/Protein-aggregation-and-t.... Accessed February 16, 2016.
    1. Carter AW. In the biosimilar marketplace will there be 50 ways to leave your insulin? [published online ahead of print January 26, 2016]. J Diabetes Sci Technol. doi:10.1177/1932296816629488. - DOI - PMC - PubMed

Publication types